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Abstract
Ubiquitin‐specific protease 18 (USP18) is an important inhibitor of interferon (IFN) 
antiviral activity, and the aim of this study was to investigate the association between 
the USP18 mRNA level change in peripheral blood mononuclear cells (PBMCs) when 
stimulated with IFN in vitro before initiating treatment and the treatment outcomes 
in HBeAg‐positive chronic hepatitis B (CHB) patients treated with IFN. A total of 44 
patients who received standard IFN‐based anti‐HBV therapy and follow‐up were en‐
rolled in the study. The in vitro IFN‐induced USP18 mRNA change (USP18IFN‐N) was 
measured via comparison of quantitative PCR‐determined USP18 transcription levels 
of BPMCs cultured with and without IFN stimulation. Either for virological (VR) or 
serological response (SR), the baseline USP18IFN‐N was significantly higher (P = 0.018 
for VR, P = 0.008 for SR) among nonresponders (n = 23 for VR, n = 33 for SR) than 
that of responders (n = 21 for VR, n = 11 for SR). Multivariate analyses revealed base‐
line USP18IFN‐N was a novel independent predictor for either VR (OR = 0.292, 95% 
CI = 0.102‐0.835, P = 0.022) or SR (OR = 0.173, 95% CI = 0.035‐0.849, P = 0.031) in 
our cohort. In addition, baseline USP18IFN‐N in combination with HBV DNA loads or 
HBeAg levels showed improved accuracy of pretreatment prediction for VR or SR re‐
sponders, respectively. Baseline USP18IFN‐N levels are associated with both virologi‐
cal and serological response, and have the potential to become a clinical predictor for 
treatment outcomes in HBeAg‐positive CHB patients before initiating IFN‐α therapy.
K E Y W O R D S
chronic hepatitis B, interferon‐alpha, transcriptional response, treatment outcome, ubiquitin‐
specific protease 18
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1  | INTRODUC TION
Chronic hepatitis B virus (HBV) infection affects over 240 million 
people worldwide1 and is the major risk factor for the development 
of decompensated cirrhosis and hepatocellular carcinoma.2,3 The 
aim of treatment for chronic HBV infection is to prevent progression 
of the disease to cirrhosis, liver failure, hepatocellular carcinoma and 
death, and sustained suppression of HBV replication has been iden‐
tified as a key determinant for the goal of therapy.4
Currently, two types of drugs, interferon‐α (IFN‐α) and nucle‐
otide analogues, have been approved for the treatment of chronic 
hepatitis B (CHB) globally. The efficacy of both types of drugs is still 
unsatisfactory, but the advantages of IFN‐α therapy include a finite 
treatment course, absence of drug resistance and an opportunity to 
obtain a sustained off‐therapy response.5 However, treatment with 
IFN‐α leads to a response in only a minority of CHBs,6 so selection of 
patients with a high probability of response is essential for success‐
ful use of IFN‐α in clinical practice.
IFN‐α treatment leads to the transcription of hundreds of inter‐
feron‐stimulated genes (ISGs), and the products of these ISGs exert 
numerous antiviral effector functions.7‐9 It is reasonable to consider 
that the expression of ISGs induced by administration of IFN‐α in 
responders differs with that in nonresponders. In a study on chronic 
hepatitis C infection treated with combination therapy of IFN‐α and 
ribavirin, peripheral blood mononuclear cells (PBMCs) were isolated 
before initiation of therapy and incubated with or without IFN‐α, and 
then, the global induction of ISGs manifested significant difference 
between responders and nonresponders.10 However, there is still no 
report about the relationship between ISGs response to IFN‐α stim‐
ulation and outcome of IFN‐α treatment in CHBs.
Among the many ISGs, ubiquitin‐specific protease 18 (USP18) is a 
famous inhibitor of IFN‐mediated innate immunity.11,12 Using pretreat‐
ment liver biopsy specimens, the previous studies have evidenced that 
the hepatic expression levels of USP18 were significantly higher in re‐
sponders than those in nonresponders, not only in IFN‐treated chronic 
hepatitis C patients13 but also in IFN‐treated CHB patients.14 Between 
responders and nonresponders, 18 ISGs with different expression lev‐
els were identified in the hepatitis C study and 12 ISGs with different 
expression were determined in the hepatitis B study. Very interesting, 
USP18 is the only overlapped ISG between both studies.
In this study, we investigated the association between USP18 
transcriptional response in IFN‐α‐stimulated PBMCs and treatment 
outcomes of IFN‐α therapy among CHB patients. Compared with 
liver biopsy specimens, PBMCs can be collected more conveniently 
and less invasively. PBMCs from 44 hepatitis B e antigen (HBeAg)‐
positive CHB patients were collected and incubated in the presence 
and absence of IFN‐α, and the method of quantitative real‐time PCR 
was used to detect the expression of USP18 relative to β‐actin. The 
data indicated that the induction of USP18 in PBMCs was signifi‐
cantly stronger in nonresponders than that in responders, and the 
weak induction of USP18 was the independent baseline predictor 
not only for virological response but also for serological response.
2  | MATERIAL S AND METHODS
2.1 | Patients
HBeAg‐positive CHB patients before IFN‐α treatment were recruited 
from the Xiamen Municipal Hospital of Traditional Chinese Medicine 
in this study. The inclusion criteria are the following: patients were not 
treated previously with nucleoside analogues and interferon, and had 
none of contraindication with interferon listed in Asian‐Pacific clinical 
practice guidelines on the management of hepatitis B: a 2015 update, such 
as hepatic decompensation, immunosuppression, pregnancy, psychi‐
atric and the like.4 Recruited patients were treated with IFN‐α2b at a 
dose of 6 × 106 IU three times weekly for 48 weeks. Besides before 
the onset of treatment, serum alanine aminotransferase (ALT) and as‐
partate aminotransferase (AST) activity were monitored monthly, and 
HBV DNA, HBV surface antigen (HBsAg), HBeAg and anti‐HBe levels 
were determined per three months during treatment. According to 
Asian‐Pacific clinical practice guidelines on the management of hepatitis 
B: a 2015 update, virological response (VR) is defined as serum HBV 
DNA load below 2000 IU/mL, and serological response (SR) is defined 
as HBeAg seroconversion at the end of treatment.
This study was reviewed and approved by the Ethics Committee 
of the School of Public Health, Xiamen University, and written in‐
formed consent was obtained from each patient.
2.2 | Isolation of PBMCs and in vitro stimulation 
with IFN‐α
Four millilitres of heparinized peripheral venous blood from each 
pretreatment patient was drawn, and PBMCs were separated using 
standard Ficoll® Paque gradient centrifugation according to the in‐
structions of the manufacturer (GE Healthcare). Purified PBMCs 
from each subject were seeded in two wells with 4.5 × 105 cells/
well and cultured in PRMI 1640 supplemented with 2 mmol/L L‐glu‐
tamine, 10% foetal bovine serum, 100 U/mL penicillin and 100 μg/
mL streptomycin in the presence and absence of 1 × 104 IU IFN‐α2b 
for 22 ± 2 hours in 37°C with 5% carbon dioxide, respectively.
2.3 | RNA extraction
After stimulation, PBMCs of each well were immediately collected 
with centrifugation. Then, total RNA was extracted from PBMCs 
using TRIzol® reagent according to the manufacturer's instructions 
(Invitrogen Life Technologies). RNA content, purity and integrity 
were determined using Multiscan™ GO (Thermo Scientific Co., Ltd).
2.4 | Real‐time quantitative reverse transcript‐
polymerase chain reaction analysis (RT‐PCR)
Purified RNA was reverse transcribed and amplified using a One Step 
PrimeScript™ kit (Takara, Dalian, China) according to the manufac‐
turer's instructions. Primer pairs and TaqMan probes were designed 
using Primer Express, version 2.0 (Thermo Fisher Scientific Inc Logan, 
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UT): USP18 forward primer (5′‐CAG ACC CTG ACA ATC CAC CT‐3′), 
reverse primer (5′‐AGC TCA TAC TGC CCT CCA GA‐3′) and probe (5′‐
FAM‐TCT GCC ACT CCC TGT ACT TCC CC‐BQH1‐3′); β‐actin forward 
primer (5′‐CAA AGA CCT GTA CGC CAA CAC A‐3′), reverse primer (5′‐
GGA GTA CTT GCG CTC AGG AGG‐3′) and probe (5′‐FAM‐CCG ACA 
GGA TGC AGA AGG AGA TCA C‐BQH1‐3′). The real‐time RT‐PCR was 
performed using 0.2 μmol/L primers and probe, 10 μL of One Step 
RT‐PCR Buffer III, 0.4 μL of Takara Ex Taq HS, 0.4 μL of PrimeScript 
RT Enzyme Mix II and 3 μL of RNA in a total volume of 20 μL. After an 
initial reverse transcription at 42°C for 5 minutes followed by pre‐de‐
naturation at 95°C for 3 minutes, the PCR reactions were cycled 40 
times as follows: 95°C for 10 seconds and 55°C for 45 seconds.
The expression values of USP18 were normalized by β‐actin as 
endogenous control, and the normalized expression values of USP18 
in cells stimulated with or without interferon were designed as 
UPS18IFN or USP18N, respectively. Then, the fold change in USP18 
expression due to interferon stimulation (UPS18IFN‐N) was calculated 
using UPS18IFN divided by USP18N.
2.5 | Statistical analysis
The data were analysed using IBM SPSS Statistics for Windows, ver‐
sion 25.0 (IBM Corp.). Between two groups, Mann‐Whitney U test 
was performed to compare the distribution of values and Fisher's 
exact test was used to compare the proportions. Receiver operat‐
ing characteristic (ROC) curve was used to analyse the diagnostic 
performance, and the optimum cut‐off value was selected based on 
Youden's index. Univariate and multivariate analyses were conducted 
to determine predictors of treatment outcome. All analyses were two‐
tailed, and a P‐value < 0.05 was considered statistically significant.
3  | RESULTS
3.1 | Patient characteristics
Between March and October 2016, 44 treatment‐naïve, HBeAg‐
positive CHB patients who met the inclusion criteria were recruited. 
Their baseline information was listed in Table 1. Briefly, the median of 
baseline levels of serum ALT, AST, HBV DNA, HBsAg and HBeAg was 
174 U/L, 83 U/L, 7.76 log10 IU/mL, 4.47 log10 IU/mL and 3.04 log10 
s/co values, respectively. With IFN‐α2b stimulation in vitro, the me‐
dian of normalized USP18 mRNA expression levels in PBMC was in‐
creased by about 23 folds (1.37 log10), from −2.42 log10 to −1.13 log10.
After the therapy with IFN‐α2b for 48 weeks, 21 patients (47.7%) 
achieved virological response and 11 patients (25.0%) achieved se‐
rological response Table 1.
3.2 | The differences of baseline characteristics 
between patients with and without virological/
serological response
As presented in Table 2, not only between patients with and without 
virological response (VR+ and VR− patients) but also between patients 
with and without serological response (SR+ and SR− patients), there was 
no significant difference in age, gender distribution, ALT activity, AST 
activity or HBsAg level at the beginning of treatment. VR+ patients had 
significantly lower HBV DNA loads than VR− patients (P = 0.046) Table 2 
and Figure 1A, and SR+ patients had significantly lower HBeAg levels 
than SR− patients (P = 0.003) Table 2 and Figure 1C, whereas HBV DNA 
loads in SR+ and SR− patients were comparable (P = 0.069), and HBeAg 
levels in VR+ patients were the same as those in VR− patients (P = 0.888) 
Table 2. As for baseline normalized expression levels of UPS18 mRNA 
in PBMC cultured with (USP18IFN) or without IFN‐α2b (USP18N), there 
was also no significant difference between VR+ and VR− patients, or 
between SR+ and SR− patients Table 2. However, the increase in USP18 
mRNA expression levels induced by interferon (USP18IFN‐N) was signifi‐
cantly lower in VR+ patients than in VR− patients (P = 0.018) Table 2 and 
Figure 1B and was also significantly lower in SR+ patients than in SR− pa‐
tients (P = 0.008) Table 2 and Figure 1D. The median of increasing folds 
in VR+, VR−, SR+ and SR− patients was 12.9 (1.11 log10), 67.6 (1.83 log10), 
12.6 (1.10 log10) and 49.0 (1.69 log10), respectively.
3.3 | Correlation between baseline 
characteristics and treatment outcome
In order to evaluate baseline characteristics in predicting virological 
response and serological response, a multivariate regression analysis 
was conducted with inclusion of gender, age, ALT activity, AST activ‐
ity, HBV DNA load, HBsAg level, HBeAg level, USP18N level, USP18IFN 
level and USP18IFN‐N level in the model Table 3. The results showed 
that baseline USP18IFN‐N level was the only independent predictor for 
virological response (OR: 0.292, 95% CI: 0.102‐0.835, P = 0.022) and 
one of the two independent predictors for serological response (OR: 
0.173, 95% CI: 0.035‐0.849, P = 0.031). The increase of USP18 mRNA 
expression level in PBMC induced by interferon was higher, and the 
TA B L E  1   Baseline information of patients and their therapeutic 
results at end of treatment
Characteristics Values
Number 44
Gender, males/females 28/16
Age, years 30.5 (27 to 36)
ALT, U/L 174 (103 to 321)
AST, U/L 83 (61 to 147)
HBV DNA, log10 IU/mL 7.76 (6.99 to 8.20)
HBsAg, log10 IU/mL 4.47 (4.20 to 4.72)
HBeAg, log10 s/co 3.04 (2.64 to 3.11)
USP18N, log10 −2.42 (−2.89 to 1.99)
USP18IFN, log10 −1.13 (−1.50 to 0.61)
USP18IFN‐N, log10 1.37 (1.03 to 2.00)
Virological response, N (%) 21 (47.7%)
Serological response, N (%) 11 (25.0%)
Note: Data of Age, ALT, AST, HBV DNA, HBsAg, HBeAg, USP18N, 
USP18IFN and USP18IFN‐N are expressed at Median (interquartile range).
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probability that patients had virological response at end of treatment 
was lower. The other independent predictor for serological response 
was baseline HBeAg level (OR: 0.117, 95% CI: 0.019‐0.707, P = 0.019).
3.4 | Rates of virological/serological response 
among patients with favourable baseline 
characteristics
3.4.1 | Virological response
At first, the optimal cut‐off values of baseline HBV DNA load and 
USP18IFN‐N level for distinguishing VR+ and VR− patients were 
determined with ROC analysis Figure 2A. For diagnosing VR+, the 
optimal cut‐off value of baseline HBV DNA load was ≤8.00 log10 
IU/mL with 80.95% of sensitivity and 56.52% of specificity, and 
that of USP18IFN‐N level was ≤1.15 log10 with 57.14% of sensitiv‐
ity and 82.61% of specificity. Then, with these cut‐off values, pa‐
tients were grouped according to their baseline HBV DNA load and 
USP18IFN‐N level, and virological response rates in different groups 
were analysed Figure 3A. The VR+ rate in patients with low HBV 
DNA load was significantly higher than in those with high HBV 
DNA load (63% vs 24%, P = 0.025, OR: 5.535, 95% CI: 1.41‐21.65), 
meanwhile, the same results were observed in patients with low and 
high USP18IFN‐N level (75% vs 32%, P = 0.015; OR: 6.333, 95% CI: 
TA B L E  2   Baseline characteristics in patients with and without virological/serological response
Baseline 
characteristics
Virological response Serological response
+ − P value + − P value
Number 21 23 / 11 33 /
Gender, males/females 14/7 14/9 0.932 7/4 21/12 0.717
Age, years 31 (29 to 36) 30 (26.5 to 35) 0.587 32 (30 to 37.5) 30 (26 to 35) 0.271
ALT, U/L 194 (150 to 250) 174 (104.5 to 337.5) 0.833 166 (123 to 228.5) 177 (106 to 325) 0.650
AST, U/L 81 (61 to 126) 88 (60.5 to 154.5) 0.934 72 (61 to 116.5) 88 (61 to 162) 0.708
HBV DNA, log10 IU/mL 7.54 (6.88 to 8.07) 8.11 (7.21 to 8.37) 0.046 7.39 (6.72 to 7.62) 8.07 (7.13 to 8.33) 0.069
HBsAg, log10 IU/mL 4.43 (4.22 to 4.68) 4.48 (4.16 to 4.72) 0.488 4.39 (4.26 to 4.64) 4.48 (4.18 to 4.72) 0.593
HBeAg, log10 s/co 3.04 (2.63 to 3.11) 3.05 (2.78 to 3.11) 0.888 2.63 (1.78 to 2.98) 3.07 (2.95 to 3.13) 0.003
USP18N, log10 −2.42 (−2.55 to 2.04) −2.43 (−3.10 to 2.00) 0.341 −2.41 (−2.58 to 1.97) −2.43 (−2.91 to 2.05) 0.538
USP18IFN, log10 −1.22 (−1.31 to 0.89) −0.89 (−1.56 to 0.37) 0.597 −1.22 (−1.45 to 1.01) −0.98 (−1.48 to 0.47) 0.295
USP18IFN‐N, log10 1.11 (0.88 to 1.69) 1.83 (1.31 to 2.09) 0.018 1.10 (0.77‐1.15) 1.69 (1.27‐2.07) 0.008
Note: Data of Age, ALT, AST, HBV DNA, HBsAg, HBeAg, USP18N, USP18IFN and USP18IFN‐N are expressed at Median (interquartile range). ‘+’ repre‐
sents response, and ‘−’ represents nonresponse. Yates‐corrected chi‐square test was employed to compare ratios between two groups, and Mann‐
Whitney U test was employed to compare numerical values between two groups.
F I G U R E  1   Distribution of baseline 
characteristics with significant difference 
between virological/serological response 
and nonresponse patients. A, The 
distribution of baseline HBV DNA load 
in VR± patients, B, the distribution of 
baseline USP18IFN‐N in VR± patients, C, 
the distribution of baseline HBeAg level 
in SR± patients and D, the distribution of 
baseline USP18IFN‐N in SR± patients. Bars 
indicate median and interquartile range. 
Mann‐Whitney U test was employed to 
compare values between two groups
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1.591‐25.22). The highest VR+ rate (92%) occurred in group with 
both low baseline characteristics, which was significantly higher 
than that in groups with only low HBV DNA load (40%, P = 0.018), 
with only low USP18IFN‐N level (25%, P = 0.046) and with both high 
baseline characteristics (23%, P = 0.002).
3.4.2 | Serological response
With ROC analysis Figure 2B, the optimal cut‐off values of baseline 
HBeAg and USP18IFN‐N levels for distinguishing SR+/SR− patients 
were determined as ≤2.94 log10 s/co (72.73% of sensitivity and 
75.76% of specificity for diagnosing SR+) and ≤1.21 log10 (81.82% 
of sensitivity and 75.76% of specificity for diagnosing SR+), respec‐
tively. Then, the patients were grouped according to their baseline 
HBeAg and USP18IFN‐N level with these cut‐off values, and the SR+ 
rates in groups with different baseline characteristics were analysed 
Figure 3B. The significantly higher SR+ rate was observed in patients 
with low HBeAg level than those with high HBeAg level (50% vs 
11%, P = 0.011, OR: 8.333, 95% CI: 1.773‐39.16), and the SR+ rate 
was also significantly higher in patients with low USP18IFN‐N level 
than those with high USP18IFN‐N level (52% vs 8%, P = 0.002, OR: 
14.06, 95% CI: 2.502‐79.05). As the same as observed for virological 
response, the highest SR+ rate (100%) occurred in group with double 
low baseline characteristics, which was significantly higher than that 
in groups with single low HBeAg level (0%, P < 0.001), with single 
low USP18IFN‐N level (11%, P = 0.001) and with double high baseline 
characteristics (11%, P < 0.001).
3.5 | Kinetics of HBsAg, HBeAg, HBV DNA and 
serum transaminases in patients with different 
USP18IFN‐N level
Because there was only one patient with USP18IFN‐N level between 
1.15 log10 (the optimal cut‐off value for virological response) and 
1.21 log10 (the one for serological response), the 44 patients 
were simply classified into two groups according to their baseline 
USP18IFN‐N levels (≥1.21 log10, 17 patients and <1.21 log10, 27 pa‐
tients), and the kinetics of HBsAg, HBeAg, HBV DNA and serum 
transaminases in the period of treatment were analysed in the 
two groups, respectively. As for HBsAg, HBeAg and HBV DNA, 
their levels in group with USP18IFN‐N levels ≥ 1.21 log10 decreased 
more rapidly than those in group with USP18IFN‐N levels < 1.21 
log10 Figure 4A‐C. Although the sample size was small, the mean 
decline folds of HBsAg, HBeAg and HBV DNA levels manifested 
TA B L E  3   Baseline variables associated with virological response and serological response
Baseline variables
Univariate Multivariate
OR 95% CI P value OR 95% CI P value
Virological response
Gender 0.778 0.226‐2.673 0.690    
Age 1.034 0.955‐1.118 0.412    
ALT level 0.999 0.997‐1.002 0.461    
AST level 0.999 0.994‐1.003 0.507    
HBV DNA level 0.485 0.223‐1.053 0.067    
HBsAg level 0.619 0.157‐2.445 0.619    
HBeAg level 0.659 0.253‐1.714 0.392    
USP18N level 1.599 0.737‐3.467 0.235    
USP18IFN level 0.868 0.393‐1.915 0.725    
USP18IFN‐N level 0.292 0.102‐0.835 0.022 0.292 0.102‐0.835 0.022
Serological response
Gender 1.000 0.242‐4.131 1.000    
Age 1.013 0.932‐1.101 0.758    
ALT level 0.999 0.995‐1.002 0.512    
AST level 0.998 0.993‐1.004 0.598    
HBV DNA level 0.520 0.249‐1.085 0.081    
HBsAg level 0.811 0.176‐3.748 0.789    
HBeAg level 0.174 0.046‐0.664 0.010 0.117 0.019‐0.707 0.019
USP18N level 1.236 0.516‐2.959 0.635    
USP18IFN level 0.521 0.197‐1.377 0.189    
USP18IFN‐N level 0.199 0.051‐0.776 0.020 0.173 0.035‐0.849 0.031
Note: Data of Age, ALT, AST, HBV DNA, HBsAg, HBeAg, USP18N, USP18IFN and USP18IFN‐N are expressed at Median (interquartile range). ‘+’ 
represents response, and ‘−’ represents nonresponse. Yates‐corrected chi‐square test was employed to compare ratios between two groups, and 
Mann‐Whitney U test was employed to compare numerical values between two groups.
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significant difference (P < 0.05) between the two groups on 
some time points after beginning of treatment, such as HBsAg, 
HBeAg and HBV DNA at week 24 as well as HBV DNA at week 36 
Figure 4A‐C. During the treatment, HBeAg loss occurred in 11 out 
of 44 patients, 9 in group with USP18IFN‐N levels < 1.21 log10 and 
2 in that with USP18IFN‐N levels ≥ 1.21 log10. The seroconversion 
of anti‐HBe was observed in all of the 11 patients, and HBeAg 
relapse was observed in none of them until the end of treatment 
at week 48. As for serum ALT and AST, no significant difference in 
their mean decline folds was observed between the two groups, 
respectively Figure 4D and 4.
4  | DISCUSSION
In this study, we demonstrated that clinical outcome of IFN‐α ther‐
apy in CHB patients is associated with the transcriptional response 
of USP18 to IFN‐α in in vitro cultured PBMCs. Previously, Xiao et al14 
reported that the hepatic expression of USP18 in CHB patients with 
nonresponse to IFN‐α therapy was significantly higher than that in 
patients with response, but two major differences exist between 
their and this studies. The first, instead of liver tissue, PBMCs were 
collected as specimens in this study, which is more convenient in 
clinic. Secondly, the expression levels of USP18 in PBMCs treated 
with or without IFN‐α (USP18IFN or USP18N) were measured, respec‐
tively, and the fold changes of USP18 expression (USP18 response 
to IFN, USP18IFN‐N) were calculated in this study, whereas only the 
intrinsic expression levels of USP18 (USP18N) in pretreatment liver 
tissues were determined in their study. Maybe due to not the same 
type of specimens used in the two studies, the difference in USP18N 
between responders and nonresponders was not observed in this 
study.
USP18, also known as ubiquitin protease 43 (UBP43), is an IFN‐
inducible cysteine protease of the ubiquitin‐specific protease fam‐
ily.15 It acts as an important inhibitor of innate immunity against viral 
infection via two independent ways, deconjugating the ubiquitin‐like 
protein ISG15 from target proteins and inhibiting IFN‐induced JAK‐
STAT signal transduction.16,17 When USP18 is knockout or knock‐
down, many viruses exhibit less replication in mice or cells, such as 
lymphocytic choriomeningitis virus,18 vesicular stomatitis virus,18 
human immunodeficiency virus,19 hepatitis C virus20 and avian in‐
fluenza virus.21 As for HBV, Kim et al22 found that the level of HBV 
DNA replication was substantially reduced in the USP18‐deficient 
mice. Li et al23 reported that the expression and replication of HBV 
were inhibited in HepG2.2.15 cells by USP18 knockdown with RNA 
interference, and suppression of USP18 enhances the anti‐HBV ac‐
tivity of IFN‐α through JAK‐STAT signalling pathway. In this study, 
higher induction of UPS18 was the independent predictor for not 
only virological nonresponse but also serological nonresponse to 
treatment with IFN‐α, which is consistent with the role of USP18 as 
a negative regulator of IFN antiviral activity.
The overall patterns of ISG induction were remarkably similar in 
PBMCs treated with IFN in vitro and in vivo,24 and the global tran‐
scriptional response to IFN in PBMCs cultured in vitro was associ‐
ated with the treatment outcome of chronic hepatitis C patients.10 
Using PBMCs as the specimens in this study, we demonstrate that 
USP18 response to IFN‐α is a determinant of CHB treatment out‐
come, which also evidences that the response in PBMCs treated in 
vitro may, to some extent, reflect the response in liver tissues when 
the patients are administrated with IFN‐α.
F I G U R E  2   ROC curves of baseline 
characteristics with significant difference 
between VR+ and VR− patients or 
between SR+ and SR− patients. A, ROC 
curves of HBV DNA load and USP18IFN‐N 
level for the identification of patients with 
virological response at end of treatment. 
B, ROC curves of HBeAg level and 
USP18IFN‐N level for the identification of 
patients with serological response at end 
of treatment
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Although a relatively small set of patients were examined in 
this study, some arguments suggest that the results are broadly 
applicable. First, the finding that the expression of USP18 was 
induced higher in nonresponders is consistent with its role of 
inhibiting IFN antiviral activity. Meanwhile, the previous studies 
also demonstrated that higher USP18 expression exists in pre‐
treated liver tissues of nonresponders when chronic hepatitis C 
viral infection or chronic HBV infection was treated with IFN.13,14 
Second, the results of USP18IFN‐N in VR− and SR− CHBs patients 
were mutually validated. It was significantly higher in both nonre‐
sponders (VR− and SR−) than in their corresponding responders 
Figure 1B and 1. Third, low baseline USP18IFN‐N as a predictor for 
VR+ or SR+ is independent of confounding factors, such as gen‐
der, age, ALT and AST activities, HBV DNA load as well as HBsAg 
F I G U R E  3   Virological/Serological 
response rate in patients with different 
baseline characteristics. A, virological 
response rate and B, serological response 
rate. The boxes and bars indicate response 
rates and 95% CIs. Two groups were 
compared with Fisher's exact test
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and HBeAg levels. The last, higher rate of VR+ in patients with 
lower baseline HBV DNA loads and higher rate of SR+ in those 
with lower baseline HBeAg levels are observed in this study, which 
have been reported elsewhere.25,26
Different from HBV DNA load and HBeAg level, which are virus‐
related factors, USP18 is an important regulator of IFN response. So, 
the combination of the virus‐related factors and USP18IFN‐N mani‐
fested higher effectiveness to predict virological response or serolog‐
ical response Figure 3. In patients with both lower baseline HBV DNA 
loads and USP18IFN‐N levels, the rate of VR+ increases to 92% from 
63% in patients with lower HBV DNA loads and 75% in those with 
lower USP18IFN‐N levels. For serological response, the rate of SR+ was 
50% in patients with lower baseline HBeAg levels or 52% in those with 
lower USP18IFN‐N levels, but it reached 100% in double‐lower group.
In conclusion, our study demonstrated that the USP18 transcrip‐
tional response to IFN‐α is associated with the outcome of IFN‐α 
treatment in HBeAg‐positive CHBs, and lower level of USP18IFN‐N in 
pretreatment PBMCs was a good predictor for not only virological 
response but also serological response. Meanwhile, combination of 
baseline USP18IFN‐N levels and virus‐related factors, such as HBV 
DNA load and HBeAg level, significantly enhanced the ability to 
identify virological responders and serological responders, respec‐
tively. These findings will facilitate the understanding of the mech‐
anisms for nonresponse to IFN‐α treatment in CHBs and indicate 
that USP18IFN‐N of PBMCs has the potential to become a clinic pre‐
dictor for treatment outcomes in CHB patients before the initiation 
of IFN‐α therapy.
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